Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af effektivitet og sikkerhed af LNP023 hos deltagere med aktiv lupus nefritis klasse III-IV, +/- V

10. november 2026 opdateret af: Novartis Pharmaceuticals

Et adaptivt, randomiseret, dobbeltblindt, dosisudforskning, parallelgruppe, placebokontrolleret, multicenter fase 2-forsøg til evaluering af effektivitet, sikkerhed og tolerabilitet af LNP023 i kombination med standardbehandling med og uden orale kortikosteroider hos patienter med aktiv lupus Nefritis klasse III-IV, +/- V

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Studieoversigt

Detaljeret beskrivelse

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

81

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Santa Fe, Argentina, S3000EPV
        • Novartis Investigative Site
      • Salvador, Brasilien, 40323-010
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 40150-150
        • Novartis Investigative Site
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasilien, 30150-221
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasilien, 05403-000
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasilien, 04038-002
        • Novartis Investigative Site
      • Montería, Colombia, 230004
        • Novartis Investigative Site
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080020
        • Novartis Investigative Site
    • Cundinamarca
      • Bogota, Cundinamarca, Colombia, 111411
        • Novartis Investigative Site
    • Santander Department
      • Bucaramanga, Santander Department, Colombia, 680003
        • Novartis Investigative Site
      • Cambridge, Det Forenede Kongerige, CB2 0QQ
        • Novartis Investigative Site
      • Quezon, Filippinerne, 1102
        • Novartis Investigative Site
    • National Capital Region
      • Makati City, National Capital Region, Filippinerne, 1218
        • Novartis Investigative Site
    • California
      • San Bernardino, California, Forenede Stater, 92408
        • Loma Linda University
    • Illinois
      • Hinsdale, Illinois, Forenede Stater, 60521
        • Nep Assoc of Northern Illinois
      • Marseille, Frankrig, 13005
        • Novartis Investigative Site
      • Nantes, Frankrig, 44093
        • Novartis Investigative Site
    • Hong Kong
      • Hong Kong, Hong Kong, Hong Kong, 999077
        • Novartis Investigative Site
    • Kerala
      • Kozhikode, Kerala, Indien, 673008
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indien, 110029
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Indien, 500082
        • Novartis Investigative Site
      • Shenzhen, Kina, 518036
        • Novartis Investigative Site
    • Guangxi
      • Nanning, Guangxi, Kina, 530022
        • Novartis Investigative Site
    • Ningxia
      • Yinchuan, Ningxia, Kina, 750004
        • Novartis Investigative Site
      • Selangor Darul Ehsan, Malaysia, 68100
        • Novartis Investigative Site
    • Pahang
      • Kuantan, Pahang, Malaysia, 25100
        • Novartis Investigative Site
    • Perak
      • Taiping, Perak, Malaysia, 34000
        • Novartis Investigative Site
      • Aguascalientes, Mexico, 20230
        • Novartis Investigative Site
      • Veracruz, Mexico, 91900
        • Novartis Investigative Site
    • Tamaulipas
      • Tampico, Tamaulipas, Mexico, 89440
        • Novartis Investigative Site
    • Yucatán
      • Mérida, Yucatán, Mexico, 97070
        • Novartis Investigative Site
      • Coimbra, Portugal, 3004-561
        • Novartis Investigative Site
    • Singapore
      • Singapore, Singapore, Singapore, 308433
        • Novartis Investigative Site
    • Melikgazi
      • Kayseri, Melikgazi, Tyrkiet (Türkiye), 38039
        • Novartis Investigative Site
    • Yenimahalle
      • Ankara, Yenimahalle, Tyrkiet (Türkiye), 06500
        • Novartis Investigative Site
    • Yenisehir
      • Mersin, Yenisehir, Tyrkiet (Türkiye), 33110
        • Novartis Investigative Site
      • Mainz, Tyskland, 55131
        • Novartis Investigative Site
    • Lower Saxony
      • Braunschweig, Lower Saxony, Tyskland, 38126
        • Novartis Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.

Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.

eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.

First presentation or flare of lupus nephritis.

Exclusion Criteria:

Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.

Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.

Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.

Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.

Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)

Other protocol-defined inclusion/exclusion criteria may apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Iptacopan + standard of care (part 1)

Iptacopan + standard of care

Taken for 52 Weeks

Andre navne:
  • LNP023
Placebo komparator: Placebo matching iptacopan + standard of care (part 1)

Placebo matching iptacopan standard of care

Taken for 52 Weeks

Aktiv komparator: Iptacopan + standard of care (part 2)

Iptacopan + standard of care

Taken for 52 Weeks

Andre navne:
  • LNP023
Aktiv komparator: Iptacopan + placebo (part 2)

Iptacopan + placebo standard of care

Taken for 52 Weeks

Andre navne:
  • LNP023 og placebo
Aktiv komparator: Placebo matching iptacopan + standard of care (part 2)

Placebo matching iptacopan + standard of care

Taken for 52 Weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Tidsramme: Baseline and week 24

Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone

Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g.

Baseline and week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Tidsramme: Baseline, week 24, week 52

Proportion of patients achieving complete renal response or partial renal response

Baseline, week 24, week 52
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Tidsramme: Baseline, week 24 week 52

Frequency of renal flares between weeks 24 and 52

Baseline, week 24 week 52
Log-transformed ratio to baseline of 24h UPCR at week 24
Tidsramme: Baseline week 24

Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit)

Baseline week 24
Change from baseline FACIT-Fatigue Score
Tidsramme: Weeks 24 and 52

Measure fatigue in patients

Weeks 24 and 52
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Tidsramme: Weeks 24 and 52

Measure disease activity in SLE

Weeks 24 and 52
Change from baseline in BILAG-2004 score at weeks 24 and 52
Tidsramme: Weeks 24 and 52

Measure disease activity

Weeks 24 and 52
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Tidsramme: Week 24 and Week 52

Measurement of time to complete renal response based on urine samples

Week 24 and Week 52

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. august 2022

Primær færdiggørelse (Faktiske)

19. marts 2026

Studieafslutning (Faktiske)

1. oktober 2026

Datoer for studieregistrering

Først indsendt

24. februar 2022

Først indsendt, der opfyldte QC-kriterier

24. februar 2022

Først opslået (Faktiske)

7. marts 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner